Supporters and Exhibitors
The BMJD Congress would like to thank the supporters. It is with the support of the industry that BMJD can continue in its mission to promote research and education and to disseminate new knowledge.
TRB Chemedica International SA is a Swiss pharmaceutical company, with a focus on research, development and marketing of innovative niche products in rheumatology.
Our product portfolio consists of:
• DIACEREIN, an oral interleukin-1 inhibitor for the treatment of osteoarthritis with beneficial symptom- and structure-modifying effects.
• OSTENIL® Line, i.a. hyaluronic acid-based injections for the symptomatic treatment of osteoarthritis of large and small joints.
• OSTENIL® TENDON, hyaluronic acid-based injection for the treatment of pain and restricted mobility in tendon disorders.
For more information please visit www.trbchemedica.com
Our product portfolio consists of:
• DIACEREIN, an oral interleukin-1 inhibitor for the treatment of osteoarthritis with beneficial symptom- and structure-modifying effects.
• OSTENIL® Line, i.a. hyaluronic acid-based injections for the symptomatic treatment of osteoarthritis of large and small joints.
• OSTENIL® TENDON, hyaluronic acid-based injection for the treatment of pain and restricted mobility in tendon disorders.
For more information please visit www.trbchemedica.com
Samumed, LLC is a pharmaceutical platform company that has made groundbreaking advances in the biology of tissue regeneration. Our platform is rooted in its discoveries of new targets and biological processes in the Wnt pathway, an essential component of cellular biology of tissue regeneration. Samumed researchers are developing and testing drug therapies that regulate tissue regeneration and/or target other causes of diseases such as systemic inflammation. Samumed is currently conducting clinical trials in osteoarthritis, degenerative disc disease, idiopathic pulmonary fibrosis, psoriasis, tendinopathy, androgenetic alopecia, and oncology.
For more information please visit www.samumed.com
For more information please visit www.samumed.com
Advanced Therapeutics within Everyone’s Reach- Celltrion Healthcare is a global biopharmaceutical company committed to delivering high-quality and affordable therapeutics for patients.
We believe that every patient deserves access to treatments they need. Based on this belief, Celltrion Healthcare has been steadfast in our mission to meet the needs of patients who previously had limited access to advanced therapeutics since our inception in 1999 by developing biosimilar products. As a result, our biosimilar products have been approved in over 80 countries and being prescribed in more than 60 countries.
For more information please visit www.celltrionhealthcare.com
We believe that every patient deserves access to treatments they need. Based on this belief, Celltrion Healthcare has been steadfast in our mission to meet the needs of patients who previously had limited access to advanced therapeutics since our inception in 1999 by developing biosimilar products. As a result, our biosimilar products have been approved in over 80 countries and being prescribed in more than 60 countries.
For more information please visit www.celltrionhealthcare.com
Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; and impact the future through passionate global leadership. We offer a growing portfolio of more than 7,500 marketed products around the world. We market our products in more than 165 countries. We are one of the world’s largest producers of active pharmaceutical ingredients. Every member of our approximately 35,000-strong workforce is dedicated to creating better health for a better world.
For more information please visit www.mylan.com
For more information please visit www.mylan.com
LG Chem, the leading chemical company, has strengthened market dominance starting from the Basic Materials & Chemicals business to Energy Solution, IT and Electronic Materials and Life Science area.
Life Sciences Company focuses at four major healthcare services including pharmaceutical, vaccine, medical device and biopharmaceutical.
Based on its own fundamental technology, LG Chem expanded its pipeline to include biosimilars in order to improve patient access to highly effective biological products.
LG Chem will continue to improve the quality of life by providing innovative portfolio of medicines across the world.
For more information please visit www.lgchem.com
Life Sciences Company focuses at four major healthcare services including pharmaceutical, vaccine, medical device and biopharmaceutical.
Based on its own fundamental technology, LG Chem expanded its pipeline to include biosimilars in order to improve patient access to highly effective biological products.
LG Chem will continue to improve the quality of life by providing innovative portfolio of medicines across the world.
For more information please visit www.lgchem.com
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. Founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism
For more information please visit www.lilly.com
For more information please visit www.lilly.com
Shandong ORLIFE Pharmaceutical Co.,Ltd (山东源生制药有限公司) is an innovative biotechnology company in stem cell therapy and regenerative medicine. ORLIFE is located in Tai’an high-tech Zone, Shandong Province, China. It is a China&Korea joint venture by MEDIPOST and Shandong Jingyuan Biotechnology Co.,Ltd. The first product for ORLIFE to exploit China market is CARTISTEM®–world’s first & only allogeneic stem cell drug for treatment of knee cartilage defects in patients with Osteoarthritis caused by degeneration or repetitive trauma. Patients of all ages over 18 years are eligible to receive the treatment. It was confirmed that 97.7% of patients examined 1 year post-treatment showed cartilage regeneration after single treatment with CARTISTEM®.
For more information please visit www.orlife.com.cn
For more information please visit www.orlife.com.cn
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. Our colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For over 150 years, we have worked to make a difference for all who rely on us.
For more information please visit www.pfizer.com
For more information please visit www.pfizer.com
Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
For more information please visit www.sanofi.com
With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.
For more information please visit www.sanofi.com
Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide. We reimagine medicine to improve and extend people’s lives. We use innovative science and technology to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible.
For more information please visit www.novartis.com
For more information please visit www.novartis.com
TRB Chemedica International is a market-leading pharma and biotechnology company, based in Switzerland and operating around the world.
For over 30 years, we have been successfully developing, producing, and promoting APIs, pharmaceutical products, and medical devices in three specialized areas: ophthalmology, rheumatology, and neurology.
Our medium-sized company backed up by an exclusive network of subsidiaries, agents, and partners makes us efficient and responsive in the market, with the ability to develop custom solutions for patients and partners.
As a family firm from our foundation, we have strong values that are shared by everyone from the boardroom to the factory.
For more information please visit www.trbchemedica.com
For over 30 years, we have been successfully developing, producing, and promoting APIs, pharmaceutical products, and medical devices in three specialized areas: ophthalmology, rheumatology, and neurology.
Our medium-sized company backed up by an exclusive network of subsidiaries, agents, and partners makes us efficient and responsive in the market, with the ability to develop custom solutions for patients and partners.
As a family firm from our foundation, we have strong values that are shared by everyone from the boardroom to the factory.
For more information please visit www.trbchemedica.com
The 22nd Asia Pacific League of Associations for Rheumatology (APLAR 2020) co-hosted by the Japan College of Rheumatology (JCR) will be held from 31 August – 3 September, 2020 in Kyoto, Japan. APLAR 2020 will provide breaking clinical information and be a forum for the exchange of cutting-edge scientific research. The congress will facilitate the networking of industry specialists and professionals from around the globe through a comprehensive and innovative program including scientific sessions, special interest groups, industry symposia and an exhibition where the latest industry advances can be discussed with senior representatives from a variety of organisations.
For more information please visit www.aplar2020.com
For more information please visit www.aplar2020.com